Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cassava Sciences Inc
(NQ:
SAVA
)
28.80
+0.29 (+1.03%)
Streaming Delayed Price
Updated: 2:59 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cassava Sciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Cassava ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. and Encourages Investors to Contact the Firm
February 05, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
February 05, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
February 05, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Cassava Sciences Inc. (NASDAQ: SAVA) Leading the Way in Tuesday Trading Based on Percentage Gain
October 17, 2023
Via
Investor Brand Network
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
January 05, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
December 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
High short interest stocks: this popular trend is re-emerging
December 11, 2023
Renewed optimism has led to higher risk tolerance in stocks, which has brought back a popular trend: Stocks with high short interest are gaining popularity
Via
MarketBeat
Topics
ETFs
Cassava Sciences Appoints Three New Members to its Board of Directors
December 07, 2023
Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
November 07, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
November 06, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
October 25, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
October 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
October 05, 2023
CEO to Present on Wednesday, October 11th, at 10:30am ET
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
October 02, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
September 18, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
September 11, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
September 06, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
August 03, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
July 05, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
New Research Shows Simufilam Suppresses Overactive mTOR
June 27, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
New Publication Highlights Basic Science Supporting Simufilam
June 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
May 11, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
May 08, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
May 01, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
April 26, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
February 28, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
February 08, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
January 30, 2023
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Via
MarketBeat
Exposures
Product Safety
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
January 24, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.